BioCryst halts en­roll­ment in all stud­ies for its lead pipeline can­di­date — shares crash

BioCryst is tak­ing a beat­ing Fri­day morn­ing af­ter re­port­ing it would pause en­roll­ment in three stud­ies for its lead pipeline pro­gram.

In a terse state­ment put out right be­fore the mar­ket opened, the Durham, NC-based biotech said it dis­cov­ered el­e­vat­ed serum cre­a­ti­nine lev­els in some pa­tients, and will halt re­cruit­ment while it in­ves­ti­gates. El­e­vat­ed cre­a­tine lev­els can be a sign of kid­ney dys­func­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER